Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for future performance [4][7]. Core Insights - In the first half of 2025, the company achieved revenue of 507 million yuan, a year-on-year increase of 40.47%, and a net profit attributable to shareholders of 110 million yuan, up 211.25% year-on-year [1]. - The significant growth in performance is attributed to the successful implementation of the Thailand production base and the rising prices of natural vanillin products due to global supply-demand changes [2][3]. - The company is focusing on developing a fourth product system based on biosynthesis technology, which aims to diversify its product line and meet new market demands [4]. Business Performance Summary - Revenue from synthetic flavors, cooling agents, and natural flavors in the first half of 2025 was 127 million yuan, 124 million yuan, and 253 million yuan, respectively, with varying gross margins [2]. - The Thailand production base has reached near full production capacity, contributing significantly to the company's sales and profits [3]. - The company plans to expand its Thailand base with a new synthetic vanillin production line, expected to add 4,000 tons of capacity [3]. Financial Forecast - The projected net profits for 2025, 2026, and 2027 are 260 million yuan, 342 million yuan, and 406 million yuan, respectively, with corresponding PE ratios of 20X, 15X, and 13X [4][6]. - The company is expected to see substantial revenue growth, with estimates of 1.78 billion yuan in 2025, representing a growth rate of 123.4% [6][10].

Core Viewpoint - The company has experienced significant revenue growth in 2024, but net profit has declined due to intense price competition in the spice industry [2] Group 1: Financial Performance - In 2024, the company achieved a revenue of 797 million yuan, representing a year-on-year increase of 26.42%, while net profit attributable to shareholders was 56 million yuan, down 30.51% [2] - In Q1 2024, the company reported a record revenue of 262 million yuan and a net profit of approximately 82.17 million yuan, with a non-recurring net profit of 38.20 million yuan, marking a year-on-year growth of 120.8% [2] Group 2: Production Capacity and Expansion - The first phase of the "Yaxiang Biotechnology (Thailand) Co., Ltd. Production Base Project" commenced production in November 2024, with the Thai factory achieving normal full-load production [2] - The first phase capacity includes 1,000 tons of vanillin, 200 tons of oak moss, and other products, with a second phase expected to be completed around August 2025 [3] - A new synthetic vanillin production line is planned in Thailand, which will have an annual capacity of 4,000 tons [3] Group 3: Strategic Investments - The company plans to acquire 10% equity in Centrome Inc. for 30 million USD to expand sales channels and market share in the U.S. [3] - This investment is expected to enhance the company's international influence and complement its U.S. subsidiary's operations [3] Group 4: Market Strategy - The establishment of the Thai base allows the company to diversify its product structure and increase production capacity while avoiding tariff impacts [4] - The company is actively exploring new product layouts to meet diverse market demands, including the introduction of ambroxan, a fragrance ingredient commonly used in perfumes [4]

Group 1: Financial Performance - The company's net profit for 2024 is expected to decline due to four main factors: increased fixed asset depreciation, a 37% year-on-year increase in sales team size leading to higher sales expenses, increased R&D investment, and a structural decline in gross margin of core products due to intensified market competition [2][3] - In Q1 2025, the company reported a net profit growth of approximately 360%, attributed to investment income of about 40 million yuan and the efficient operation of the Thai production base [3] Group 2: Operational Insights - The Thai factory achieved approximately 90 million yuan in revenue and 19 million yuan in net profit in Q1 2025, primarily producing vanillin and cooling agents [3] - Long-term contracts account for about 80% of the company's total revenue, with pricing strategies adjusted based on market supply and demand dynamics [3][4] Group 3: Expansion and Product Development - The first phase of the Thai base is fully operational, with the second phase expected to be completed around August 2025, and the third phase in preliminary planning [3] - The company is actively exploring new product developments, such as ambroxan, to meet diverse market and consumer demands [4] - Strategic investment in ABT shares aims to strengthen sales channels and enhance market competitiveness [4]